December 2022 in “Indian Journal of Animal Research” This study found that both fluoxetine and clomipramine are effective in treating psychogenic triggers of acral lick dermatitis in dogs, with fluoxetine leading to quicker recovery and lower recurrence rates, while clomipramine showed better overall recovery rates but was associated with fewer side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” This study observed that adolescents with alopecia areata receiving ritlecitinib 50 mg daily showed notable hair regrowth over three years, as seen in both clinician- and patient-reported outcomes. However, the decreased number of participants at later stages limits the findings.
April 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” This study analyzed social media posts and found discrepancies between patient-reported satisfaction and emotional responses to alopecia areata treatments, highlighting potential gaps between perceived and clinical efficacy.
September 2022 in “Journal of Investigative Dermatology” This study found that the Severity of Alopecia Tool score does not predict the quality of life in patients with alopecia areata, suggesting patient-reported outcomes better reflect the impact on life quality.
May 2024 in “JEADV Clinical Practice” In this study, researchers found that among patients with severe alopecia areata, a change in SALT scores of 42 or 43 points represents meaningful improvement, highlighting the need to consider individual treatment goals beyond conventional low SALT score targets when assessing treatment benefits.
